Synopsis

On

Prevalence of HIV and Its Treatment

&
Marketing Strategies of CIPLA ltd.
Submitted in the partial fulfillment of

POST GRADUATE DIPLOMA IN

MANAGEMENT
BY
INSTITUTE OF MANAGEMENT STUDIES,
GHAZIABAD

Submitted to: Submitted by:-

Dr. TAPAN KUMAR NAYAK DEEPAK KUMAR DINKER
Associate Professor. PGDM 2nd Year
IMS, GHAZIABAD IMS, GHAZIABAD
 INTRODUCTION

HIV (Human Immunodeficiency) is considered as a life threaten disease

for any human being, but today the disease is curable but it will depend
upon the state of the patient. In this whole project I will work upon the
how it will transfer to the society and what is the impact of this disease in
the society. I will try to find out with the help of this report the effect of
various medicine of the various company who is producing the medicine
against HIV/AIDS.

CIPLA ltd. is a company who is producing medicine and vaccines against

many diseases. CIPLA Ltd. is manufacturing vaccines and medicines
since 1935 and now it is the top company of our country in sales. It is the
company who is consider as one of the top three pharmaceutical company
of our country. They are in the business since 1935. This company is also
in the business of exporting its medicine in 180 countries.

This company is approved by various organizations.

1. WHO (World Health Organization)

2. Food and Drug Administration (FDA, USA)

3. Therapeutic goods administration (Australia)

4. Pharmaceutical Inspection Convention (Germany)

5. National Institute Of Pharmacy (Hungary)

Marketing is the backbone of any company whether the company is any

FMCG company, consumer durable company or any pharmaceutical
company. The major task of marketing is not to launch any brand but lead
to the ultimate sale and generate revenue for the company. Marketing is a
very big term and it consists of many thing like launching new brand,
promoting the exiting the brand etc.

I also work upon the marketing strategies of all major pharmaceutical

company in the country like Ranbaxy, Sun pharma, Mankind Pharma etc.
But my major focus on the marketing strategies of CIPLA Ltd. I will try
to find out how Cipla is targeting their customer and consumer. For any
pharmaceutical company it is not possible to target their consumer
directly for this they are using some kind for marketing plan as well.

I will try to find out how cipla ltd. is using various marketing strategies
for various competitors present in the field of the medicines.
 LITERATURE REVIEW
HIV/AIDS Treatment and Prevention in India: Modeling the Costs and
Consequences.
Mead Over, Peter Heywood, Julian Gold, Indrani Gupta, Subhash Hira,
Elliot Marseille
Published date:2004

In 2004 India has as many HIV-infected people as any country in the

world. And scientists tell us that an effective vaccine against AIDS is
unlikely for at least another decade. Yet there is hope that the devastation
of the AIDS epi- demic can be slowed and even reversed in India.
Awareness of the threat of AIDS and willingness to take precautions to
prevent infection have both improved dramatically since 1990, with
condom use on high-risk sexual contacts rising from almost zero in 1990
to 50 percent nationally and to up to 85 percent in some states. These
changes have already prevented millions of infections. Further increases
in condom use on high-risk contacts can prevent millions more infections.
 OBJECTIVE

The Objective of this reports are as follows:

1. Prevalence of HIV and its treatment.

2. Marketing strategies of the CIPLA ltd.

 RESEARCH METHODOLGY
For prevalence of HIV and its treatment.(Primary Data)

1. Sample design:
Sample unit: Our sample unit is individual who is very well aware of the
disease and its treatment.
Sample size: Our sample size is 100.
Sampling method: Convenience sampling.
Sampling area: Delhi

2.Data collection
Sources: Primary data.
Tool: Questionnaire filled by individuals.

3.Data Analysis.
Statistical Tools: PASW by SPSS
Descriptive analysis (Mode, Median)
Statistical analysis (factor analysis)

For marketing strategies part I will go for primary and secondary data.
Because, may be I will not entertain by the company employee because
they don’t want to disclose their strategies but I will try to find out with
the help of chemists who is having their medicines.
 REFERENCES

APAC (AIDS Prevention and Control Project). 2002. “HIV Risk

Behaviour Surveillance Survey in Tamil Nadu. Report on the Fourth
Wave.” Tamil Nadu AIDS Prevention and Control Project, Chennai.

Adje, C., R. Cheingsong, T. Roels and 14 others. 2001. “High prevalence

of genotypic and phenotypic HIV-1 drug-resistant strains among patients
receiving antiretro- viral therapy in Abidjan, Cote d’Ivoire.” Journal of
Acquired Immune Deficiency Syndromes 26 (5):501–6.

Brigido, Luis, Rosangela Rodrigues, Jorge Casseb, Daniela Oliveira,

Milena Rossetti,
Paulo Menezes, and Alberto Duarte. 2001. “Impact of Adherence to
Antiretroviral
Therapy in HIV-1-Infected Patients at a University Public Service in
Brazil.”
AIDS PATIENTCARE and STDs15(11): 587–593.

Chakraborty, H., P.K. Sen, and others. 2001. “Viral Burden in Genital
Secretions Determines Male-to-Female Sexual Transmission of HIV-1: A
Probabilistic Empiric Model.” AIDS155:621–627.